{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61"}]}],"title":"All cause"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Cancer-related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Non-cancer related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Cause of death specified as \"unknown\""},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Cause of death not documented"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1496"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Safety population, i.e. all patients who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Number of Patients by Cause of Death","type":"PRIMARY","unitOfMeasure":"participants"}